A Pioneering Immuno-Dermatology Company
About Alys Pharmaceuticals
Alys Pharmaceuticals is a pioneering force in immuno-dermatology, poised to redefine the treatment landscape with cutting-edge science and a robust R&D-centric multi-platform pipeline.
Launched in February 2024, Alys emerges as a result of the strategic aggregation of 6 asset-centric companies backed by Medicxi.
Alys has received a total of $100M financing from Medicxi.
Alys has been structured with an operational focus around each asset class, and with focus on the dermatology vertical for optimized leverage and impact
Vision and Mission
Transforming the treatment paradigm across dermatological indications.
These range from established indications such as atopic dermatitis to emerging categories like vitiligo, alopecia areata and chronic spontaneous urticaria. Beyond these, Alys is committed to addressing underserved indications like CTCL, mastocytosis and prevention of dermatological side effects of oncology therapies. With a focus on innovation and collaboration, Alys Pharmaceuticals aims to bring hope and transformative solutions to patients worldwide.
Alys History
A Shared Vision
The advanced modalities comprising the Alys pipeline have been incubated in major institutions around the world, in the mind and hands of top technological, scientific and medical experts. These approaches have matured within six biotech companies supported by Medicxi, which shared the same vision for next generation solutions in dermatology.
Synergy under Alys
Recognizing the potential to synergize multiple assets and platforms in the same therapeutic area, Medicxi and all co-founders agreed in the last quarter of 2023 to launch Alys Pharmaceuticals by merging these six biotech companies.
Alys Pharmaceuticals now fully owns these six subsidiaries, which each retain operational autonomy under the asset-centric model, while benefiting from the world-class expertise of the overarching Alys scientific leadership team.
About the Alys Subsidiaries
Aldena Therapeutics is leveraging cutting-edge siRNA technology to unlock its potential in the skin. Aldena focuses on developing highly effective locally delivered treatments, with paradigm-shifting infrequent dosing for enhanced patient compliance.
Graegis Pharmaceuticals is dedicated to supporting the skin and mucosa through cancer therapies and to become an integral part of holistic cancer patient care. This groundbreaking approach aims to offer the first true prevention of skin radiation damage in cancers treated with radiation therapy (RT) truly designed to fit seamlessly in the patient journey.
Granular Therapeutics is shaping the future of granulocyte-targeted therapy in chronic inflammatory diseases. With an emphasis on mast cell-specific targeting, Granular aspires to be the preferred first-line option for chronic conditions such as chronic urticaria or systemic mastocytosis.
Klirna Biotech intends to revolutionize itch treatment by achieving intraneuronal targeting of molecular switches of itch. This innovative approach targets itch-specific sensory neurons for long-lasting relief in a broad array of chronic pruritic conditions.
Nira Biosciences is developing a new platform for photoimmunotherapy deployed toward immuno-dermatology, providing spatially defined, cell-targeted therapy. The Company specializes in monoclonal antibody-targeted delivery of photon absorbing moieties, particularly effective for addressing inflammatory skin disorders with precision.
Vimela Therapeutics is advancing topical therapy for vitiligo, offering an orthogonal approach to current and future immunomodulatory options for repigmentation, with a potential to improve response in refractory areas.
